Inhibition of in vivo and in vitro infectivity of Leishmania donovani by tunicamycin.
Leishmania donovani 2S strain promastigotes were rendered non-infectious to mice and mouse peritoneal macrophages by treatment with tunicamycin, an inhibitor of N-linked protein glycosylation. Concentrations of tunicamycin (1-10 micrograms ml-1) that reduced promastigote infectivity to 2% or less of control levels had little or no measurable effect on the in vitro growth of the promastigotes. Tunicamycin has no apparent effect on the entry of promastigotes into macrophages. These results indicate that the sugar residues of glycoproteins are important to the promastigote during the early stages of macrophage infection.
D000818:Animals; D002478:Cells, Cultured; D005260:Female; D005944:Glucosamine / Q000031:analogs & derivatives*; D006023:Glycoproteins / Q000096:biosynthesis / Q000502:physiology; D007891:Leishmania / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D007898:Leishmaniasis, Visceral / Q000469:parasitology; D008099:Liver / Q000469:parasitology; D008264:Macrophages / Q000469:parasitology; D051379:Mice; D008810:Mice, Inbred C57BL; D013997:Time Factors; D014415:Tunicamycin / Q000494:pharmacology*
D006023:Glycoproteins; D014415:Tunicamycin; D005944:Glucosamine